Protocol Ledger

NCT04528082 · Phase III · RECRUITING

Apremilast Pediatric Study in Children With Active Oral Ulcers Associated With Behçet's Disease

Interventional Phase III clinical trial protocol NCT04528082 sponsored by Amgen in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-09-09 Enrollment: 60 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT04528082
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)60 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04528082
Protocol FieldVerified Registry Value
NCT IdentifierNCT04528082
Consolidated Lead SponsorAmgen
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment60 participants (ESTIMATED)
Registered Start Date2021-09-09
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04528082
Hospital Research SiteLocationSite Profile
Meir Medical CenterKfar Saba, IsraelOpen Hospital Dossier ->
Hospital Universitario Virgen del RocioSeville, SpainOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Amgen across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI